- Home
- IAM vs ACHV Comparison
IAM vs ACHV Comparison
Compare IAM & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IAM | ACHV |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.0M | 726.5M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IAM | ACHV |
|---|---|---|
| Price | $15.48 | $6.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $24.67 | $14.15 |
| AVG Volume (30 Days) | 648.2K | ★ 1.3M |
| Earning Date | 11-23-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $225.80 | N/A |
| Revenue Next Year | $150.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.60 | $2.62 |
| 52 Week High | $24.49 | $8.64 |
Technical Indicators
Market Signals| Indicator | IAM | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 33.63 | 47.88 |
| Support Level | $12.52 | $5.96 |
| Resistance Level | $16.50 | $7.29 |
| Average True Range (ATR) | 1.84 | 0.40 |
| MACD | 0.31 | 0.03 |
| Stochastic Oscillator | 79.71 | 50.96 |
Price Performance
Historical ComparisonAbout IAM Iambic Therapeutics Inc. Common Stock
Iambic Therapeutics Inc is a technology and clinical-stage life sciences company developing novel medicines using its proprietary molecular superintelligence platform.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.